PHILADELPHIA, Oct. 21, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that its Medical Director, Dr. David Strayer, will present clinical data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. on October 27, 2008. ICAAC is one of the largest medical/scientific conferences held annually in U.S. The presentation, entitled "Review of the Integrative Studies Supporting an NDA for Ampligen(r) in the Treatment of Seriously Debilitating Chronic Fatigue Syndrome (CFS)," will focus on results of 13 clinical studies with Ampligen(r), an experimental biotherapeutic, with respect to improvements in exercise capacity, CFS signs and symptoms, medication use and drug safety profile following more than 90,000 Ampligen(r) injections.
